Controversies in Multiple Sclerosis

MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Yes

Antonio Scalfari

Only few multiple sclerosis (MS) patients escape the progressive course if they survive long enough. In the majority of cases, the progression supervenes after a variable latency from the onset of the relapsing remitting phase, but the clinical boundaries between the relapsing and the progressive course are often indistinct. There are no surrogate markers or universally accepted definition for the continuous unremitting disability accumulation and defining the clinical phenotypes of MS can be challenging even for experienced clinicians.

The current phenotypical distinction of relapsing remitting (RR), secondary progressive (SP) and primary progressive (PP) MS provides a standardized terminology, which enhances homogeneity in clinical trials. However, despite the variable patterns of evolution, there are no biological reasons for discerning different phenotypes. Pathological mechanisms underlying acute attacks and progression are known to be tightly intermingled and to occur concomitantly since the early phase of the disease, irrespective of clinical symptoms. The same wide spectrum of central nervous system tissue alterations is seen across all stages, with only quantitative, rather than qualitative differences. Both PP and SP MS share similar pathological features in respect of the extent of inflammatory infiltrates, axonal damage and cortical demyelination. Epidemiological data corroborate a unifying disease model of MS, with predominantly age-related clinical phenotypes. By growing older, the risk of experiencing a progressive course proportionally increases, while relapses gradually become sparse and infrequent. Progressive MS patients, with or without a preceding RR course, accumulate disability at very similar rate and share strikingly similar mean age at onset of progression, indicating that PPMS is preceded by an ‘asymptomatic RR phase’. Consistent with this view, subjects with radiologically isolated syndrome can develop a PP course years after the incidental detection of white matter abnormalities, confirming a protracted pre-progressive prodrome with subclinical disease activity similar to RRMS.

Despite being biologically active, progressive MS can remain clinically undetectable for years. Most clinicians would be reluctant to document a progressive accumulation of disability unrelated to clinical attacks during the early stage of the RR phase. Based on the recently proposed objective definition of SPMS, the attainment of at least expanded disability status scale (EDSS) of 4 is required to mark the transition to the progressive phase. However, the clinical progression can be uncovered in the early phase of the disease, among patients with no permanent motor impairment, especially when relapses with poor recovery, which can potentially cloud the progressive accumulation of disability, are uncommon. This was highlighted by George Ebers’ group by addressing the clinical course of single attack progressive MS, which is a rare phenotype distinguished by a single demyelinating episode at onset, followed some years later by the progressive phase. Because of the lack of ongoing relapses, in this subgroup, the progression mostly presented clinically with exercise-induced ambulation worsening and could be pinpointed after 8 mean years from onset, at an average EDSS of 2, therefore much earlier than in classic SPMS cases.

In line with these early intuitive observations, recent data indicate that a continuous progression independent of relapsing activity (PIRA) is commonly observed during the RR phase. The pooled analysis of the two OPERA trials demonstrated, in both the Interferon and Ocrelizumab groups with a relatively short disease duration (mean 6 years) and low baseline mean EDSS score (= 2.8), an impressively large proportion of patients (78% and 87%, respectively) accumulating disability, which was unrelated to inflammatory attacks and was mostly secondary to worsening of the walking impairment. This provides clinical evidence of an early underlying progressive course despite the
effective therapeutic relapse suppression and should caution against using the lack of ongoing focal inflammation as marker of disease stability. The adequate control of inflammatory parameters might provide a sense of false security, while a continuous smouldering process underpins the subtle clinical deterioration, which stands out as an important unmet treatment target. Changes in the whole brain and grey matter volume, the accumulation of chronic slowing expanding lesions and the microglia activation, both in the normal appearing white matter and in the perilesional areas, are plausible drivers of PIRA events during the RR phase, when the focal inflammatory activity is the dominant clinical feature, albeit representing only the tip of the pathological iceberg.

These observations challenge the dichotomy between relapsing and progressive disease, supporting a one stage disorder model of MS, where all patients exhibit a progressive course since the disease onset, which can be overlapped by relapses. Detrimental processes, spanning across all disease stages and underpinning the progressive accumulation of disability, start early and subtly emerge clinically under the strong influence of age-related biological changes, which induce immune senescence and exhaustion of compensatory mechanisms. The individual immune system proactivity accounts for the simultaneous highly variable superimposed relapsing activity, which overlaps the progressive course and additionally contributes to the disability accumulation. In this wide spectrum of age-related clinical manifestations, young patients are more likely to experience relapse onset progressive MS and display an initial floridly inflammatory course, which gradually subsides by growing older, while the subclinical neurodegeneration becomes clinically evident. At the opposite extreme lay older patients, who present with a PP course and are distinguished by a resistance to the clinical inflammatory activity, possibly related to undetermined immunological qualitative differences, compared to SPMS.

Alike other neurodegenerative disorders, such as Parkinson or Alzheimer diseases, progressive MS is preceded by a prodromal phase of unknown duration before meeting its conventional clinical definition. It remains debated whether relapses represent a concomitant epiphenomenon to the primary neuroaxonal loss, which potentially promotes the release of highly antigenic myelin fragments, secondarily triggering the innate and adaptive immune responses. This inside-out model would contrast with the traditional outside-in view of a primary process, starting in the periphery with a dysregulated immune reaction and causing an inflammatory response, which eventually lead to the axonal degeneration. The tight interconnection between neurodegenerative and inflammatory mechanisms makes the two hypotheses equally likely, leaving the question unresolved. However, evidence of early progressive accumulation of disability independent of relapses discloses a dissociation between the therapeutic suppression of the inflammatory activity and the disease progression. This highlights the need of shifting our treatments strategies to target more broadly all pathological mechanisms driving MS, with a specific focus on halting smouldering processes, which account for the progressive worsening since the early stage.

**Declaration of Conflicting Interests**
The author declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Scalfari received honoraria for participations to advisory board and conference attendances from Teva, Biogen, Novartis, Sanofi-Genzyme, Roche and Celgene.

**Funding**
The author received no financial support for the research, authorship, and/or publication of this article.

**ORCID iD**
Antonio Scalfari https://orcid.org/0000-0002-7757-0293

**References**
1. Lassmann H, van Horssen J and Mahad D. Progressive multiple sclerosis: Pathology and pathogenesis. *Nat Rev Neurol* 2012; 8: 647–656.
2. Scalfari A, Lederer C, Daumer M, et al. The relationship of age with the clinical phenotype in multiple sclerosis. *Mult Scler* 2016; 22(13): 1750–1758.
3. Confavreux C and Vukusic S. Natural history of multiple sclerosis: A unifying concept. *Brain* 2006; 129(Pt 3): 606–616.
4. Kantarci OH, Lebrun C, Siva A, et al. Primary progressive multiple sclerosis evolving from radiologically isolated syndrome. *Ann Neurol* 2016; 79(2): 288–294.
5. Lorscheider J, Buzzard K, Jokubaitis V, et al. Defining secondary progressive multiple sclerosis. *Brain* 2016; 139: 2395–2405.
6. Kremenchutzky M, Rice GP, Baskerville J, et al. The natural history of multiple sclerosis: A geographically
MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – No

Anne H Cross and Robert T Naismith

The “primary progressive MS” nomenclature indicates steadily progressive neurodegeneration, perhaps punctuated by periods of quiescence, but with an overall relentless downhill course and without improvements. It also implies the steady loss of axons within the central nervous system (CNS), most frequently associated with an impairment in ambulation. The reasons for the progressive axonal loss are not fully known but likely to be multifactorial.

We contend that not all multiple sclerosis (MS) is progressive from the beginning. Extrapolating this stance, we argue that not all people with MS have a steady loss of CNS axons beyond what occurs naturally with aging or in association with relapses. The other side of this debate might argue that progressive MS can be obscured by overlying relapses and by neuroplasticity. We base our stance that progressive MS is not present from MS initiation in all people with MS upon the following pillars: (1) clinical cases of bona fide “benign” MS lasting for decades and (2) imaging evidence of non-progression in some persons with MS.

Although identifying benign MS before the requisite decades of follow-up remains controversial, benign MS undoubtedly exists. We argue that benign MS would not exist in a substantial proportion if all people with MS have underlying progressive MS, even accounting for possible periods of quiescence. The Multiple Sclerosis Severity Score was based on the Expanded Disability Status Scale (EDSS) scores of 9892 primarily European MS patients in relation to their disease durations. These MS patients were being followed at dedicated MS centers, suggesting that the majority had the correct diagnosis of MS. The average disease duration of the patients in the study was 11.7 years. The study included several hundred people with 15 or more years duration of MS, 25% of whom had EDSS of 2.5 or less, which is close to a normal neurological examination. Over 200 people were followed more than 20 years. Even after 20 years disease duration, 15% had an EDSS of 2.5 or lower. These proportions were similar to those derived in a London Ontario MS cohort, supporting their veracity and the existence of a population of MS patients with long-standing, minimally altered neurological examinations.

In the United States, the New York State MS Consortium (NYSMSC) reported a retrospective study of over 6000 persons with MS, and observed that 19.8% of NYSMSC patients qualified as benign. A conservative definition of EDSS ≥2 with >10 years duration since symptom onset was adopted and the mean duration since symptom onset was 17 ± 6.7 years. We argue that it is difficult to reconcile cases of MS that remain without significant disability accumulation for 15 or 20 years as having underlying progressive disease even after accounting for neuroplasticity.

Some may argue that benign MS does not adequately capture all types of impairment due to its reliance on the EDSS and ambulation. In particular, the EDSS does not sufficiently capture cognitive dysfunction. A recent study of cognition in benign MS found that after an extensive battery of 16 neuropsychological tests, cognitive dysfunction was identified in only 8%.

Based study 9: Observations on the progressive phase of the disease. *Brain* 2006; 129: 584–594.

7. Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. *JAMA Neurol* 2020; 77: 1132–1140.

8. Dal-Bianco A, Grabner G, Kronerwetter C, et al. Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI. *Brain*. Epub ahead of print 23 January 2021. DOI: 10.1093/brain/awaa436.

9. Sucksdorff M, Matilainen M, Tuisku J, et al. Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis. *Brain* 2020; 143: 3318–3330.

10. Musella A, Gentile A, Rizzo FR, et al. Interplay between age and neuroinflammation in multiple sclerosis: Effects on motor and cognitive functions. *Front Aging Neurosci* 2018; 10: 238.